Apotex Establishes Decade-Long Commitment to I-many Integrated Contract Lifecycle Management Solution

I-many, Inc. (NASDAQ:IMNY), the leading provider of advanced Contract Lifecycle Management (CLM) solutions for managing corporate commitments, today announced that Apotex, the largest Canadian-owned pharmaceutical company, is extending their six-year relationship with I-many for another five years by signing a license agreement to upgrade to and maintain the latest generations of I-many CARS® and I-many Government Pricing™. Along with Apotex’s already-implemented latest generation of I-many Medicaid, these state-of-the-art solutions will enable Apotex to optimize revenues while meeting growing regulatory challenges in the U.S. and emerging ones in Canada. "We have been completely satisfied with our existing I-many CLM solution but recognize that we have to adapt that solution as the regulatory environment changes,” said Michael Davidson, CIO at Apotex. "With the anticipated release of new regulations in Ontario and other provinces in Canada, as well as the challenge of complying with a wide variety of U.S. regulations such as DRA, we consider I-many Government Pricing to be an essential tool. Our commitment to the next generation of I-many CARS was similarly made out of a desire to take an evolutionary approach to rebate and chargeback processing. The solution will make it easier to manage these processes and optimize revenues, while also dramatically reducing end-user training requirements because of its simplified, Web-based user interface.” "We are delighted that Apotex and over 19 other Life Sciences customers have extended their long-term commitment to I-many,” said John A. Rade, I-many’s president and CEO. "This demonstrates the confidence and loyalty our customers have with us in delivering not only market-leading products, but industry-leading services as well. As the regulatory burden in Canada for pharmaceutical companies becomes increasingly complex, we are confident other companies doing business in Canada will also find the I-many family of integrated CLM solutions to be the ideal way of meeting these challenges while protecting revenues.” About Apotex Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its two-employee, 5,000-square-foot beginning, the company has grown to employ over 6,300 people in research, development, manufacturing and distribution facilities world-wide. Apotex produces more than 300 generic pharmaceuticals in over 4,000 dosages and formats which, in Canada, are used to fill over 75 million prescriptions a year and is the largest amount of any pharmaceutical company in Canada. For more information, please visit www.apotex.com. About I-many® I-many (NASDAQ:IMNY) is the leading provider of advanced Contract Lifecycle Management solutions for managing corporate commitments. Designed to extend beyond the traditional contract management capabilities, I-many ContractSphere® offers an end-to-end solution, from pre-contract processes and contract management to transaction compliance. Ultimately, this provides companies with the visibility and control needed to manage any type of commitment – from contracts and obligations to payments and collections. The result is increased revenue, minimized risk and dramatically reduced operating costs, which deliver improved profitability with hard return on investment. More than 280 customers across 21 industries worldwide have implemented and realized the value of I-many business solutions. For more information, please visit www.imany.com. This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include: the risk of unforeseen technical or practical impediments to planned software development and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission.